pharmaceutical investing La Jolla Pharmaceutical Company Gets European Commission Approval for GIAPREZA
pharmaceutical investing La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118
pharmaceutical investing La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118
pharmaceutical investing La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA
Golconda Gold Releases Q2 2026 Production Update at Galaxy And Announces Mobilisation of Mining Contractor at Summit
New Report from KBR Supports Potential for US$1.75/kg Hydrogen from Syntholene's Geothermal-SOEC Platform
